bioengineer.org /2 weeks ago

Anti-CGRP Migraine Drugs Cut Monthly Headache Days by Nearly Half in Catalan Cohort

A Catalan registry study of 5438 patients found anti-CGRP antibody treatment cut monthly migraine days by about 45 percent while spending surpassed 18 million euros.

Read source
cafepharma.com /2 weeks ago

Argenx

Argenx Anonymous (not verified) Thu, 11/05/2026 - 18:31 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
cafepharma.com /1 month ago

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
pharmexec.com /6 days ago

<![CDATA[FDA Approves Klygefa for gMG, Gazyva for Primary Membranous Nephropathy, Igalmi for Agitation Associated wit...

Read source
pharmexec.com /2 days ago

<![CDATA[Innogen Licenses GLP-1 Therapy Efsubaglutide Alfa to Arcera]]>

Read source
biopharmadive.com /1 month ago

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

Read source
pharmexec.com /1 month ago

<![CDATA[FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease]]>

Read source
qchron.com /4 weeks ago

Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Genera...

The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.